AKAP1 and obesity disorder: In order to test whether AKAP1 has the potential to serve as a target for obesity treatment, two peptides spanning full length (30 aa) or core region (21 aa) of the mitochondrial targeting domain in AKAP1, which were, respectively, named as AP‐30 and AP‐21, were synthetized and used as an competitive inhibitor to block localization of AKAP1 onto the OMM as previously described.[19] We first preliminarily investigated the effect of two peptides on HFD‐induced obesity by a short‐term treatment (daily subcutaneous injection into interscapular BAT area for 7 days).